Open access Peer reviewed journalwww.actualgyn.com
Obesity, an ongoing pandemic, is associated with obesity-related androgenic, reproductive, and metabolic comorbidities in females. Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrinopathy that commonly manifests with hyperandrogenic, reproductive, and metabolic dysfunctional features. Obesity and PCOS often coexist. Insulin resistance and subsequent hyperinsulinemia are key factors implicated in the clinicopathological manifestations of PCOS and associated metabolic syndrome. Obesity may amplify these effects, thus, affecting adolescent girls and women of childbearing age. Evidence supports weight loss in achieving favourable endocrine, metabolic, and reproductive outcomes in women with Polycystic Ovary Syndrome and coexisting obesity. Therefore, an effective weight loss strategy should be considered as a front-line intervention in this patient population, with emphasis on fertility timeline-related management in reproductive-aged women, where applicable. This brief narrative review provides insight into the impact of obesity and weight loss on women with Polycystic Ovary Syndrome and coexisting obesity.